Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
Cochrane Database of Systematic Reviews, 2017•cochranelibrary.com
Background Epidermal growth factor receptor (EGFR) inhibitors prevent cell growth and
have shown benefit in the treatment of metastatic colorectal cancer, whether used as single
agents or in combination with chemotherapy. Clear benefit has been shown in trials of EGFR
monoclonal antibodies (EGFR MAb) but not EGFR tyrosine kinase inhibitors (EGFR TKI).
However, there is ongoing debate as to which patient populations gain maximum benefit
from EGFR inhibition and where they should be used in the metastatic colorectal cancer …
have shown benefit in the treatment of metastatic colorectal cancer, whether used as single
agents or in combination with chemotherapy. Clear benefit has been shown in trials of EGFR
monoclonal antibodies (EGFR MAb) but not EGFR tyrosine kinase inhibitors (EGFR TKI).
However, there is ongoing debate as to which patient populations gain maximum benefit
from EGFR inhibition and where they should be used in the metastatic colorectal cancer …
Background
Epidermal growth factor receptor (EGFR) inhibitors prevent cell growth and have shown benefit in the treatment of metastatic colorectal cancer, whether used as single agents or in combination with chemotherapy. Clear benefit has been shown in trials of EGFR monoclonal antibodies (EGFR MAb) but not EGFR tyrosine kinase inhibitors (EGFR TKI). However, there is ongoing debate as to which patient populations gain maximum benefit from EGFR inhibition and where they should be used in the metastatic colorectal cancer treatment paradigm to maximise efficacy and minimise toxicity.
Objectives
To determine the efficacy, safety profile, and potential harms of EGFR inhibitors in the treatment of people with metastatic colorectal cancer when given alone, in combination with chemotherapy, or with other biological agents.
cochranelibrary.com
以上显示的是最相近的搜索结果。 查看全部搜索结果